covid – Page 21 – Philippine Society for Microbiology and Infectious Diseases

Interim Guidelines in the Prevention and Control of COVID-19…

January 16, 2021
by psmid_user

PSN-PSMID-PHICS Interim Guidelines in the Prevention and Control of COVID19 Infection in Hemodialysis Facilities

Patients undergoing regular hemodialysis are considered vulnerable and thus require specific guidelines in the context of COVID-19. The goal is to minimize the risk of transmission of SARS-CoV-2 in facilities that provide routine hemodialysis services to this specific group of immunocompromised individuals. This document will guide nephrologists, physicians and other healthcare professionals practicing in hemodialysis units as they attend to patients seeking hemodialysis services in their facilities. Recommendations in this rapid guidance are based on best available evidence and will be updated as new evidence becomes available.

You may download a copy of the PSN-PSMID-PHICS Interim Guidelines in the Prevention and Control of COVID19 Infection in Hemodialysis Facilities here.

PSN-PSMID-PHICS-Interim-Guidelines-in-the-Prevention-and-Control-of-COVID-VERSION-2.0

Info-graphics

DOH: PH Genomic Biosurveillance Detects SARS-COV-2 UK Variant

January 13, 2021January 13, 2021
by psmid_user

Videos

Difference of SARS-CoV-2 and the new UK Strain Variant

January 13, 2021January 13, 2021
by psmid_user

Dr. Cynthia Saloma of the Philippine Genome Center explains the difference of SARS-CoV-2 and the new UK Strain Variant. (Source: Department of Health)

Videos

CNN Philippines: The changing face of Covid-19

January 8, 2021
by psmid_user

Videos

DOH Special Media Forum on the New UK Variant

January 8, 2021
by psmid_user

Emerging Infections

SARS-COV-2 Vaccine Tracker

January 7, 2021January 7, 2021
by psmid_user

Statements

HPAAC: A Call for Safe and Transparent Use of…

December 30, 2020December 30, 2020
by psmid_user

The Healthcare Professionals Alliance Against COVID-19, the alliance of more than 160 health professions organizations in the country, is alarmed that some Filipinos are receiving vaccines against COVID-19 that have not been registered with the Philippine Food and Drug Administration (FDA). In relation to this issue, there are three critical points of concern:

1. In keeping with public safety, we strongly discourage the use of vaccines that are not yet approved by the Philippine FDA.

2. Even if a vaccine is approved in other countries, its storage, transport, and distribution are complex procedures. Improper handling can damage vaccines and can render them useless. This is why distribution channels and processes need to be transparent and regulated.

Emerging Infections

What is the sensitivity of SARS-CoV-2 RT-PCR done on…

November 20, 2020
by psmid_user

For any questions or information, please email covidrapidreviewteam@gmail.com.

clinical specimen pediatric abridged

>> Return to Rapid Reviews list.

Emerging Infections

What clinical characteristics and patient symptoms are associated with…

November 20, 2020November 20, 2020
by psmid_user

For any questions or information, please email covidrapidreviewteam@gmail.com.

clinical outcomes pediatric Abridged

>> Return to Rapid Reviews list.

Announcements

Interim Guidance on the Clinical Management of Adult Patients…

July 29, 2020January 27, 2022
by psmid_user

> NOTE: The COVID-19 Living Clinical Practice Guidelines contains UPDATED recommendations and evidence summaries. Click here to be redirected to the COVID LCPG.

This Interim Guidance on the Clinical Management of Adult Patients with Suspected or Confirmed COVID-19 Infection (Version 3.1) is an update of the March 31, 2020 guidelines released by the Philippine Society for Microbiology and Infectious Diseases. New evidence have been published since then necessitating this update.This document is written to guide clinicians and health care workers in their COVID-19 related management decisions. It is based on available scientific evidence that is also rapidly evolving, as more is discovered about the pathophysiology of SARS CoV-2 and the pathogenesis of the disease. As such, the recommendations in this guideline are based on limited, often low-quality evidence, and need to be carefully balanced with clinical judgment. The use of investigational drugs should be discussed with the patient or a legally authorized representative carefully outlining the potential adverse reactions and the potential clinical benefits of these investigational drugs. A signed informed consent should be obtained by the clinician.

DOWNLOAD the Interim Management Guidelines for COVID-19 (Version 3.1) here.

Final PCP-PSMID-PCCP COVID-19 Guidelines 20July2020b

Tag: <span>covid</span>

PSN-PSMID-PHICS Interim Guidelines in the Prevention and Control of COVID19 Infection in Hemodialysis Facilities